DK0724581T3 - Krystallinsk vandfri mycophenolatmofetil og intravenøs formulering deraf - Google Patents

Krystallinsk vandfri mycophenolatmofetil og intravenøs formulering deraf

Info

Publication number
DK0724581T3
DK0724581T3 DK94928054T DK94928054T DK0724581T3 DK 0724581 T3 DK0724581 T3 DK 0724581T3 DK 94928054 T DK94928054 T DK 94928054T DK 94928054 T DK94928054 T DK 94928054T DK 0724581 T3 DK0724581 T3 DK 0724581T3
Authority
DK
Denmark
Prior art keywords
mycophenolate mofetil
crystalline anhydrous
intravenous formulation
anhydrous mycophenolate
crystalline
Prior art date
Application number
DK94928054T
Other languages
English (en)
Inventor
Jeffrey S Fleitman
Roger Cherng Fu
De-Mei Leung
Michele C Rizzolio
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Application granted granted Critical
Publication of DK0724581T3 publication Critical patent/DK0724581T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK94928054T 1993-09-15 1994-09-12 Krystallinsk vandfri mycophenolatmofetil og intravenøs formulering deraf DK0724581T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12184193A 1993-09-15 1993-09-15
PCT/US1994/010142 WO1995007902A1 (en) 1993-09-15 1994-09-12 Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof

Publications (1)

Publication Number Publication Date
DK0724581T3 true DK0724581T3 (da) 1999-08-02

Family

ID=22399119

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94928054T DK0724581T3 (da) 1993-09-15 1994-09-12 Krystallinsk vandfri mycophenolatmofetil og intravenøs formulering deraf

Country Status (31)

Country Link
US (2) US5543408A (da)
EP (1) EP0724581B1 (da)
JP (1) JP3411038B2 (da)
KR (1) KR100349772B1 (da)
CN (1) CN1060770C (da)
AT (1) ATE173475T1 (da)
AU (1) AU677435B2 (da)
BR (1) BR9407469A (da)
CA (1) CA2171836C (da)
CZ (1) CZ292423B6 (da)
DE (1) DE69414720T2 (da)
DK (1) DK0724581T3 (da)
ES (1) ES2123831T3 (da)
FI (1) FI119639B (da)
HU (1) HU217300B (da)
IL (1) IL110970A (da)
LT (1) LT4052B (da)
LV (1) LV11326B (da)
MX (1) MXPA94007099A (da)
NO (1) NO314727B1 (da)
NZ (1) NZ273801A (da)
PH (1) PH30685A (da)
PL (1) PL178522B1 (da)
RO (2) RO118075B1 (da)
RU (1) RU2132849C1 (da)
SG (1) SG55006A1 (da)
SI (1) SI9420052B (da)
TW (1) TW370527B (da)
UA (1) UA49797C2 (da)
WO (1) WO1995007902A1 (da)
ZA (1) ZA947088B (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
IN188985B (da) * 1998-12-09 2002-11-30 Biocon Ltd
CZ292123B6 (cs) * 2001-06-08 2003-08-13 Ivax Pharmaceuticals S.R.O. Způsob přípravy mykofenolátu mofetilu
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
US20050187170A1 (en) * 2003-06-16 2005-08-25 Biocryst Pharmaceuticals, Inc. Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
DE602004015310D1 (de) * 2003-09-11 2008-09-04 Sandoz Ag Verfahren zur herstellung von mycophenolatmofetil
WO2005105768A2 (en) * 2004-04-26 2005-11-10 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Process for preparation of mycophenolic acid and ester derivatives thereof
MXPA06005658A (es) * 2004-04-27 2007-04-10 Teva Gyogyszergyar Zartkoruen Proceso para preparacion de micofenolato mofetil, y otros esteres de acido micofenolico.
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
TWI322147B (en) * 2004-07-20 2010-03-21 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Crystalline mycophenolate sodium
CN100383520C (zh) * 2004-09-20 2008-04-23 复旦大学 一种测定人血浆中霉酚酸及其代谢物的方法
EP1917010A2 (en) * 2005-02-08 2008-05-07 Aspreva Pharmaceuticals SA Compositions and methods for treating vascular, autoimmune and inflammatory diseases
WO2006086498A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
US20080281111A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
EP2436381A1 (en) 2006-06-27 2012-04-04 Sandoz AG Crystallization of hydrohalides of pharmaceutical compounds
CN101953807A (zh) * 2010-10-09 2011-01-26 山西普德药业有限公司 一种注射用吗替麦考酚酯冻干粉针剂及其制备方法
MX386935B (es) 2013-03-14 2025-03-04 Alkermes Pharma Ireland Ltd Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US9168246B2 (en) 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
JP6337135B2 (ja) 2014-02-24 2018-06-06 アルカーメス ファーマ アイルランド リミテッド フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用
WO2018167628A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
GB2591396B (en) 2018-08-18 2023-06-07 Ftf Pharma Private Ltd Pharmaceutical suspension for oral dosage
CA3212370A1 (en) 2021-03-03 2022-09-09 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328213A (en) * 1979-11-28 1982-05-04 Schering Corporation Stable injectable labetalol formulation
US4478829A (en) * 1983-04-28 1984-10-23 Armour Pharmaceutical Company Pharmaceutical preparation containing purified fibronectin
SU1170760A1 (ru) * 1984-02-20 1996-09-20 Ф.Ю. Рачинский Дигидробромид 2-(2-морфолиноэтилтио)бензимидазола, повышающий физическую работоспособность и ускоряющий процессы восстановления после физических нагрузок и длительного стресса
US4753935A (en) 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
FR2653999A1 (fr) * 1989-11-06 1991-05-10 Adir Nouveaux derives de la morpholine, leur procede de preparation et les compositions pharmaceutiques les renfermant.

Also Published As

Publication number Publication date
RO118075B1 (ro) 2003-01-30
LT96028A (en) 1996-08-26
HUT75119A (en) 1997-04-28
WO1995007902A1 (en) 1995-03-23
ZA947088B (en) 1996-03-14
PL313480A1 (en) 1996-07-08
CZ78896A3 (en) 1996-10-16
EP0724581B1 (en) 1998-11-18
NO961075D0 (no) 1996-03-15
UA49797C2 (uk) 2002-10-15
RU2132849C1 (ru) 1999-07-10
RO118427B1 (ro) 2003-05-30
PL178522B1 (pl) 2000-05-31
SI9420052B (sl) 2004-02-29
FI119639B (fi) 2009-01-30
PH30685A (en) 1997-09-16
AU677435B2 (en) 1997-04-24
JPH09502721A (ja) 1997-03-18
LV11326A (lv) 1996-06-20
ES2123831T3 (es) 1999-01-16
FI961169L (fi) 1996-03-13
FI961169A0 (fi) 1996-03-13
CZ292423B6 (cs) 2003-09-17
KR100349772B1 (ko) 2002-12-28
IL110970A (en) 1999-01-26
JP3411038B2 (ja) 2003-05-26
HK1012624A1 (en) 1999-08-06
NO961075L (no) 1996-03-15
CA2171836C (en) 2006-11-14
MXPA94007099A (es) 2004-01-23
TW370527B (en) 1999-09-21
DE69414720T2 (de) 1999-04-08
SG55006A1 (en) 1998-12-21
US5543408A (en) 1996-08-06
LT4052B (en) 1996-10-25
HU9600652D0 (en) 1996-05-28
CN1131420A (zh) 1996-09-18
HU217300B (hu) 1999-12-28
AU7723894A (en) 1995-04-03
IL110970A0 (en) 1994-11-28
DE69414720D1 (de) 1998-12-24
BR9407469A (pt) 1996-11-12
EP0724581A1 (en) 1996-08-07
SI9420052A (en) 1996-12-31
CN1060770C (zh) 2001-01-17
ATE173475T1 (de) 1998-12-15
NZ273801A (en) 1997-10-24
NO314727B1 (no) 2003-05-12
US5545637A (en) 1996-08-13
CA2171836A1 (en) 1995-03-23
LV11326B (en) 1996-10-20

Similar Documents

Publication Publication Date Title
BR9407469A (pt) Micofenolato mofetil anidro cristalino e formulação intravenosa do mesmo
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
MX9702380A (es) Nuevas carboxamidas con actividad antifungica.
ATE203019T1 (de) Neue (r)-5-carbamoyl-8-fluor-3-n,n- disubstituierte-amino-3,4-dihydro-2h-1- benzopyrane
CA2171275A1 (en) Stilbene derivatives and pharmaceutical compositions containing them
DE19875032I2 (de) Mometason-Furoate-Monohydrat, Verfahren zu seiner Herstellung und das enthaltende pharmazeutische Zusammensetzungen
CA2108903A1 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
ZA922297B (en) Crystalline tiababine monohydrate,its preparation and use
GEP20032953B (en) Antitumor Agents
DE68929368D1 (de) Cephemderivate und Verfahren zu ihrer Herstellung
DK0561846T3 (da) 4,5-dihydroxy- og 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracencarboxylsyre-dicarbonater og -urethaner med terapeutisk virkning
ATE35812T1 (de) Gamma-butyrolactonderivate, verfahren zur herstellung derselben und dieselben als aktive bestandteile enthaltende immunomodulierende zubereitungen.
TW252979B (da)
NO931011L (no) 7-okso-7h-pyrido(1,2,3-de)(1,4)benzoksacin-6-karbonsyrer og -estere
WO1990003172A3 (en) Bile acids for treatment of viral infections
GEP20033054B (en) 2,4,4-Trisubstituted-1,3-Dioxolane Antifungals
EP0127389A3 (en) N,n-diethyl-5-methyl-2h-1-benzothiopyrano-(4,3,2-cd)-indazole-2-ethanamine, compositions comprising the same and uses therefor
ES2104416T3 (es) Glicosilamidas de 2-aminoacilamino-2-desoxi-azucares.
EP0733364A4 (en) MIDIZINAL PREPARATION FOR THE CIRCUIT SYSTEM
ES2076517T3 (es) Ergolinas disustituidas en posiciones 2,13, su preparacion y utilizacion en medicamentos.
GT199300041A (es) Derivados de hidrazona, proceso para producir los mismos, insecticidas y/o acaricidas que contienen dichos derivados co-mo ingrediente activo y compuestos intermedios para producir dichos derivados.